Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians

Overview

Journal Ann Intern Med

Specialty General Medicine

Date 2023 Jan 2

PMID 36592456

Authors

Amir Qaseem

Lauri A Hicks

Itziar Etxeandia-Ikobaltzeta

Tatyana Shamliyan

Thomas G Cooney

J. Thomas Cross Jr

Nick Fitterman

Jennifer S Lin

Michael Maroto

Adam J. Obley

Jeffrey A Tice

Janice E. Tufte

Affiliations

Soon will be listed here.

Abstract

Description: This guideline updates the 2017 American College of Physicians (ACP) recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults.

Methods: The ACP Clinical Guidelines Committee based these recommendations on an updated systematic review of evidence and graded them using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.

Audience And Patient Population: The audience for this guideline includes all clinicians. The patient population includes adults with primary osteoporosis or low bone mass.

Recommendation 1a:

Recommendation 1b:

Recommendation 2a:

Recommendation 2b:

Recommendation 3:

Recommendation 4:

Citing Articles

Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review.

Migliorini F, Maffulli N, Colarossi G, Filippelli A, Memminger M, Conti V Eur J Med Res. 2025; 30(1):170.

PMID: 40087804 DOI: 10.1186/s40001-025-02412-x.

Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.

Zhang Q, Gao W, Xu X, Cui R, Su B Osteoporos Int. 2025; .

PMID: 40038109 DOI: 10.1007/s00198-025-07448-7.

Analysis of the association between mixed exposure to multiple metals and comorbidity of osteopenia or osteoporosis: baseline data from the Chinese Multi-Ethnic Cohort study (CMEC).

Zhang Y, Chen C, Wu S, Nie C, Hu Y, Zhong J BMC Public Health. 2025; 25(1):680.

PMID: 39972432 PMC: 11837480. DOI: 10.1186/s12889-025-21825-1.

Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system.

Lo J, Chandra M, Khan M, Barzilay J, Carbone L, Ott S Osteoporos Int. 2025; .

PMID: 39915333 DOI: 10.1007/s00198-024-07372-2.

Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass.

Ha J, Kim J, Jeong C, Lee J, Lim Y, Baek K Arch Osteoporos. 2025; 20(1):17.

PMID: 39888520 DOI: 10.1007/s11657-024-01475-3.

References

Simpson E, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P . Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Bone. 2019; 130:115081. DOI: 10.1016/j.bone.2019.115081. View

Crandall C, Hunt R, LaCroix A, Robbins J, Wactawski-Wende J, Johnson K . After the initial fracture in postmenopausal women, where do subsequent fractures occur?. EClinicalMedicine. 2021; 35:100826. PMC: 8176125. DOI: 10.1016/j.eclinm.2021.100826. View

Mori T, Crandall C, Ganz D . Cost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide. JBMR Plus. 2019; 3(11):e10233. PMC: 6874180. DOI: 10.1002/jbm4.10233. View

Cosman F, Crittenden D, Ferrari S, Lewiecki E, Jaller-Raad J, Zerbini C . Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J Bone Miner Res. 2018; 33(8):1407-1416. DOI: 10.1002/jbmr.3439. View

Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2006; 22(3):465-75. DOI: 10.1359/jbmr.061113. View

Albert S, Reddy S . CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS. Endocr Pract. 2017; 23(7):841-856. DOI: 10.4158/EP161678.RA. View

Marques A, Ferreira R, Santos E, Loza E, Carmona L, Da Silva J . The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74(11):1958-67. DOI: 10.1136/annrheumdis-2015-207907. View

Hiligsmann M, Reginster J, Tosteson A, Bukata S, Saag K, Gold D . Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.... Osteoporos Int. 2018; 30(1):45-57. PMC: 6331734. DOI: 10.1007/s00198-018-4744-x. View

Ayers C, Kansagara D, Lazur B, Fu R, Kwon A, Harrod C . Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2023; 176(2):182-195. DOI: 10.7326/M22-0684. View

10.

Barrionuevo P, Gionfriddo M, Castaneda-Guarderas A, Zeballos-Palacios C, Bora P, Mohammed K . Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review. J Clin Endocrinol Metab. 2019; 104(5):1631-1636. PMC: 7296202. DOI: 10.1210/jc.2019-00193. View

11.

Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M . Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res. 2021; 16(1):533. PMC: 8393477. DOI: 10.1186/s13018-021-02678-x. View

12.

Qaseem A, Wilt T, Forciea M, Kansagara D, Crandall C, Fitterman N . Disclosure of Interests and Management of Conflicts of Interest in Clinical Guidelines and Guidance Statements: Methods From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2019; 171(5):354-361. DOI: 10.7326/M18-3279. View

13.

. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2004; 921:1-164, back cover. View

14.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

15.

Qaseem A, Kansagara D, Lin J, Mustafa R, Wilt T, Forciea M . The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods. Ann Intern Med. 2019; 170(12):863-870. DOI: 10.7326/M18-3290. View

16.

Qaseem A, Snow V, Shekelle P, Hopkins Jr R, Forciea M, Owens D . Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008; 148(9):680-4. DOI: 10.7326/0003-4819-148-9-200805060-00008. View

17.

Hiligsmann M, Williams S, Fitzpatrick L, Silverman S, Weiss R, Reginster J . Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019; 49(2):184-196. DOI: 10.1016/j.semarthrit.2019.01.006. View

18.

Kanis J, Johansson H, Harvey N, Lorentzon M, Liu E, Vandenput L . An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines : A report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int. 2021; 32(10):1951-1960. DOI: 10.1007/s00198-021-05942-2. View

19.

Sarafrazi N, Wambogo E, Shepherd J . Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018. NCHS Data Brief. 2021; (405):1-8. View

20.

Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T . Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis. Calcif Tissue Int. 2013; 94(2):170-5. PMC: 3899450. DOI: 10.1007/s00223-013-9777-8. View